You just read:

Immune Pharmaceuticals Reports Encouraging Preliminary Data with Bertilimumab in an Open Label Phase 2 Study in the Rare Dermatological Auto-Immune Disease, Bullous Pemphigoid

News provided by

Immune Pharmaceuticals Inc.

Feb 28, 2017, 08:30 ET